Herceptin Approved In Japan For Early Treatment In Patients With HER2-positive Breast Cancer
Roche announced that its majority-owned subsidiary Chugai Pharmaceutical Co. Ltd received approval from the Japanese Health Authority for the use of Herceptin in the early treatment for women with HER2-positive breast cancer.
More: continued here
Filed under: Breast Cancer on March 3rd, 2008